Incorporated in 1984, Concord Biotech Limited is an India-based R&D-driven biopharma company and manufacturer of fermentation-based APIs across immunosuppressants and oncology.
Financial Results:
Concord Biotech Ltd reported Revenues for Q3FY25 of ₹237.00 Crores up from ₹241.00 Crore year on year, a rise of 30.22%.
Total Expenses for Q3FY25 of ₹141.00 Crores up from ₹110.00 Crores year on year, a rise of 28.18%.
Consolidated Net Profit of ₹77.00 Crores up 32.76% from ₹58.00 Crores in the same quarter of the previous year.
The Earnings per Share is ₹18.39, Sales 32.78% from ₹13.85 in the same quarter of the previous year.
![](data:image/svg+xml;charset=utf-8,<svg height="781px" width="640px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
